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Introduction. Patients with metastatic gallbladder cancer (GBC) are generally considered incurable and compelled to 
palliative chemotherapy. Nevertheless, there are numerous reports of successful surgical management of metastatic GBC. 
The impact of such treatment is yet unclear.
Material and methods. We conducted a systematic literature review within Medline and Scopus databases using the 
following  pattern: “gallbladder” and “cancer” and “dissemination”. Also, our own experience with two resected metastatic 
GBC patients was added to the results.
Discussion. The literature search yielded 8 publications with a total of hundred and twelve patients fullling the inclusion 
criteria. Two additional patients were included in the analysis: one with resected GBC liver metastasis and the second with 
resected GBC diaphragmatic metastasis. A total of hundred and fourteen patients who underwent resection of a solid organ 
GBC metastasis were analyzed. The study conrmed a rare long-term survival after resection of an isolated GBC metastasis.
Conclusions. There is no clear indication for surgical management of gallbladder cancer metastasis. In selected cases, an 
aggressive surgical approach may be justied.
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Introduction
Gallbladder cancer (GBC) is the most common malignancy of 
the biliary tract and the fth among cancers of the gastrointe-
stinal tract. Risk factors of GBC include: cholelithiasis, a variety 
of congenital disorders and chronic inammation. The disease 
has a peak incidence between the 6th and 7th decades of life 
[1]. It is usually diagnosed at an advanced stage, as it lacks 
specic symptoms at early stages [2]. At advanced stages, 
it is characterized by rapid progression and may frequently 
spread to adjacent organs, such as: regional and non-regional 
duodenum, lymph nodes, peritoneum, pancreas, colon, and 
liver, which is the most frequent solid organ with metastasis 
from the GBC.
Since laparoscopy is frequently the rst attempt at GBC 
(mainly in patients with no pre-operative suspicion of GBC), 
cancer implants in trocar sites can also be found by several 
patients [3]. The typical pre-operative staging includes: ultra-
sonography, computer tomography (CT) and magnetic reso-
nance imaging (MRI). Most patients with stage IVb according 
to the 8th edition of the UICC TNM classication (tumor that 
has spread to tissues or organs far away from the gallbladder 
including lymph nodes) are not normally candidates for cu-
rative resection [4]. However, there are several reports, mainly 
from Japan, proving successful surgical management of me-
tastatic GBC. The impact of such treatment on patients’ health 
is unclear. The aim of this study was to evaluate the benets 
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of surgical approach in patients with isolated resectable solid 
organ metastasis from GBC.
Methods
We have searched the available medical literature for studies 
reporting outcomes of surgical resection of solid organ me-
tastasis of GBC. Since in the vast majority of patients, port-site 
metastasis is associated with concurrent or future di!use pe-
ritoneal disease and death [5, 6], we have decided to limit our 
analysis to isolated solid organ metastases, excluding port-site 
metastasis. 
The PubMed and Scopus databases were searched using 
the keywords “gallbladder” and “cancer” and “dissemination”. The 
literature review yielded 115 results. Based on the abstracts’ 
analysis, 43 studies were excluded due to the following reasons: 
• 3 studies on veterinary surgery, 
• 7 studies about metastases of cancers other than GBC, 
• 19 studies about cancers other than GBC, 
• 8 basic science studies, 
• 3 studies that did not concern metastasis, 
• 3 studies describing the operative technique. 
The remaining papers were evaluated in full text version. 
At this stage, studies were excluded based on the following: 
• 10 studies depicting massive spread to the peritoneal 
cavity, 
• 13 studies on peritoneal implants after laparoscopy, 
• 10 studies on evaluation of inoperable tumors, 
• 7 studies on basic research, 
• 12 studies on patients without metastasis, 
• 9 commentaries, 3 studies about other cancers,
• 1 epidemiology paper. 
Of the remaining 7 studies [7–13], after a thorough ana-
lysis of the texts, we have excluded 3 further studies [8, 9, 13] 
because we have failed to extract the data of patients with 
resectable metastasis of GBC. Based on cross-referencing of 
the remaining 4 studies, we have added to this systematic 
review 5 more studies fullling the search criteria [14–17]. In 
the nal analysis, we have included 8 studies. 
Results
The eight papers included in this review describe altogether 
a hundred and twelve patients with solid organ metastasis 
from GBC. The results of the treatment of a hundred and twelve 
patients combined with data on two patients treated in Maria 
Skłodowska-Curie Institute – Oncology Center, Kraków Branch 
are presented in Table I. 
Table I. The results of aggressive surgical treatment of 112 patients included in this study
Study Number 
of patients
Survival R0 Median 
survival
(months)
Notes
1. Yagi et al. 2 1 patient – 
24 months
2 patient alive 
with no evidence 
of disease after 
unknown time
2 Not given Long survival possible after radical resection
2. Nishio et al. 25  3-y – 8% Not given Not given The survival for patients with isolated liver metastasis 
was better than that for patients with other distant 
metastasis 
3. Shimuzi et al. 16 3-y – 14.4% Not given Not given Long survival possible after radical resection
4. Higuchi et al. 39 5-y – 4 patients in 
the R0 group
12 Not given Long survival possible after radical surgery
5. Kondo et al.  
(Br J Surg 2002)
10 1-y – 37% Not given 6.6 Limited distant metastasis is associated with worse 
survival
3-y – 7%
5-y – 3%
numbers calculated 
for all M1 patients
6. Yamaguchi et al. 2 Not given Not given Not given Perineural invasion and lymph node metastasis were 
identied as signicant independent prognostic 
factors in patients with GBC
7. Chijiwa et al. 7 Approaching 0 after 
20 months
Not given Not given Patients with resected liver metastases have a 
prognosis similar to nonresected stage IV patients
8. Kondo et al. 
(Langenbeck’s 
Arch Surg 2002)
11 Not given Not given Not given No further data available. Possibly overalpping with 
position 5
9. Current cases 2 23 months 
15 months
2 Not given One case of synchronous liver metastasis treated with 
simultaneos R0 resection
One case of metachronous diaphragmatic metastasis 
treated with R0 resection. Long survival possible
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All 8 papers in this review come from the Japanese centers 
and 2 papers (17, 18) originate from the same research team. 
The authors of the present systematic review tried but failed 
to contact members of this team to conrm whether these 
2 papers represent an overlapping group of patients.  
In the paper by Yamaguchi et al [12], the authors reviewed 
their experience with 68 GBC patients that included 2 patients 
with liver metastasis. Based on the data from this paper, it 
was impossible to extract data concerning these particular 
2 patients. The survival data from this paper included in Table I 
represent the numbers for the whole GBC group. The paper 
by Yagi reports only 2 patients, but with impressive survival 
numbers [14]. The paper by Nishio et al. reports the results of 
the surgical treatment of a 166 patients with stage IV GBC. The 
data on 25 patients with the resection of liver metastasis could 
be extracted from the paper [15]. Also, the paper by Shimizu et 
al. describing the results of the treatment of stage IV GBC, allo-
wed for the extraction of data on 16 patients with resectable 
liver metastasis [16]. In the paper by Higuchi et al., the authors 
report 274 patients with advanced GBC. Of these, 61 patients 
had liver metastasis including 39 with single metastasis. The 
resection was possible for 12 patients from the latter allowing 
for 5-year survival of 4 patients [7]. From the group of 37 pa-
tients with stage IV GBC described by Chijiiwa et al., 7 patients 
with liver metastases could be identied [10]. In the rst of the 
2 papers by Kondo et al. from Nagoya, the authors focused on 
the mode of tumor spread and its inuence on prognosis in 
a 112 patients with advanced GBC [18]. While it was possible 
to identify 11 patients with hepatic metastasis in this group, 
no further conclusions about this particular group could be 
drawn from the paper. In the second paper from Nagoya team 
describing a 116 patients with advanced GBC, the data on 30 
patients with metastatic disease was identied. This group 
included 10 patients with liver metastases. The survival was 
calculated for the entire cohort of M1 patients that included 
also 24 patients with metastases in para-aortic lymph nodes 
and 3 patients with peritoneal metastasis [17].
In Table I we have also included 2 patients fullling inclu-
sion criteria, operated on in second author's institution (MSCI-
-OCKB). One patient underwent simultaneous radical resection 
of GBC and the resection of a single metastasis in segment V of 
the liver. She presented with disseminated disease 6 months 
after surgery and is alive with disease 23 months after surgery. 
The second patient underwent resection of the right diaph-
ragm due to metachronous GBC metastasis 35 months after 
primary surgery. She presented with disseminated disease 7 
months after surgery for diaphragmatic metastasis and is alive 
with disease 15 months after surgery. 
Discussion 
Advanced gallbladder cancer (GBC) is associated with poor 
prognosis [19]. All stage IV GBC patients who do not undergo 
resection die within 20 months of diagnosis [10] and their 
median survival approaches 5.8 months [20]. Depending on 
the general status of a patient, treatment with chemotherapy, 
radiotherapy or palliative care is suggested [11]. Patients re-
ceiving palliative surgery and chemotherapy tend to survive 
less than 12 months [18]. However, there are isolated reports 
about longer survival following radical resection of a primary 
tumor and GBC metastasis. In this systematic review, we have 
looked at the available data on these patients. The small size of 
the group and the lack of data on adjuvant and neoadjuvant 
treatment did not allow us for the analysis of treatment options 
other than radical surgery. 
All identied papers were authored by Japanese surgical 
teams and two papers came from the same team [17, 18]. This 
nding is probably a reection of a more radical approach to 
GBC cancer in Japan, but at the same time it makes it di!cult 
to extrapolate the results to other populations. Microscopic 
liver metastasis not seen on pre-operative and intra-operative 
imaging were found on specimen analysis of 6/44 patients 
with GBC and liver resection in the paper by Yagi et al. [14]. 
This group included 2 patients with R0 resection described in 
Table I. One of these patients survived 24 months and another 
was alive with no evidence of disease after an undened period 
of time. The status of liver invasion in this group was found to 
be one of the prognostic factors on multivariate analysis. In 
the group of 25 patients reported by Nishio et al. with resected 
isolated liver metastasis from GBC, there were 2 patients survi-
ving more than 5 years (8% 5-years OS). The survival of patients 
undergoing only the resection of liver metastasis was better 
than of those with other distant metastasis and better than 
in non-resected patients. The authors concluded that a small 
percentage of patients can have an important survival advan-
tage from a radical approach to isolated liver GBC metastasis 
[15]. The risk factors for in-hospital mortality were advanced 
age, obstructive jaundice, extended hepatectomy, portal vein 
resection, and extrahepatic bile duct resection. The extended 
surgery, especially in patients with obstructive jaundice, has 
been found to be an important factor determining survival 
by increasing the risk of in-hospital mortality and morbidity in 
a paper by Shimzu et al. [16]. Interestingly, in univariate analysis 
the presence of liver metastasis detected in 16 patients was not 
found to inuence overall survival in resected GBC patients. The 
5-year survival in this group was as high as 14.4%. The authors 
concluded that R0 resection should be o"ered especially to 
those patients with liver metastases who have absent or mi-
nimal involvement of hepatoduodenal ligament and who are 
node-negative. The presence of liver metastases was found 
to inuence survival in a paper by Higuchi et al. In 12 patients 
in whom R0 resection of the liver tumors was possible, the 
5-year survival was reached in 4 patients giving a stunning 
33% 5-years OS. Unfortunately, the R0 resection was possible 
only in 12 out of 39 patients with single liver metastasis. The 
authors stated that radical surgery is not a viable option for 
patients with more than one liver lesion, but R0 resection 
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of a single liver metastasis should always be considered [7]. 
Surgery should be proposed to all stage IV GBC patients as it 
improves survival according to the paper by Chijiwa. Howe-
ver, the outcomes of treatment for patients with peritoneal 
dissemination, liver metastasis, and distant metastasis were 
similar to non-resected patients. The authors concluded that 
all IVB patients (including patients with liver metastases) are 
not good candidates for surgery, which should be limited to 
stage IVA GBC patients [10]. In this paper, the authors excluded 
patients presenting with limited, resectable liver metastasis, 
but analyzed the whole stage IVB altogether.
In the paper by Yamaguchi et al. we were able to identify 
only 2 patients with resected liver metastasis. The authors were 
not evaluating this particular group of patients, they were 
rather analyzing factors inuencing survival in the whole GBC 
cohort. Based on the analysis of 68 patients, the authors found 
that perineural invasion and lymph node metastasis were 
signicant independent prognostic factors for survival [12]. 
The group of authors from Nagoya, Japan was the only 
to publish 2 papers fullling the criteria of the present review. 
In the 2002 paper, the authors described a group of 112 GBC 
patients, of whom 11 had liver metastasis. The paper provide 
only limited data on this particular group of patients. The au-
thors stated that 2 of 47 patients with distant metastases or 
portal vein invasion survived for more than 5 years [18]. In the 
second paper by the same team, there were 30 patients with 
metastases included. The survival rates for this group were: 
37% at 1 year, 7% at 3 years and 3% at 5 years. All patients who 
underwent palliative surgery died within 1 year. Based on this 
data, the authors suggested that radical resection should be 
abandoned when GBC is associated with hepatic or any other 
metastasis [17].
The two patients in our own encounter enjoyed relatively 
long survival after resection of metastatic tumors of the liver 
and diaphragm. 
There are some important aws in this review. The data 
on the precise extent of surgery (simple metastasectomy vs. 
anatomical resection) as well as management of gallbladder 
bed are missing in some papers. The management of regional 
lymph nodes was also not described in detail in the reviewed 
papers.
Conclusions
In summary, the existing data on the surgical resection of 
solid organ metastases of GBC are scarce and contradictory. 
While some authors back radical surgery (only if R0 resection 
is achievable), others discourage this approach. The fact that 
all papers found during our review come only from 7 Japanese 
hospitals further obscures the results. It seems, however, that 
radical surgery should be taken into account in patients with 
a solitary metastasis, without hepatoduodenal lymph nodes 
involvement, with radical primary tumor resection and without 
perineural invasion, as it may result in an improvement in 
otherwise poor survival.
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